ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.

Talha Munir et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.